Biosfeen is a sphingolipids ingredient that is said to increase filaggrin expression. Filaggrin plays a role in the skin’s barrier function.
Ingredient supplier Bioiberica (Barcelona, Spain) has launched a new retail product to address atopic dermatitis in dogs and cats. The product is a collar that contains the company’s lipids-based Biosfeen ingredient for atopic dermatitis. Biosfeen is a sphingolipids ingredient that is said to increase filaggrin expression. Filaggrin plays a role in the skin’s barrier function.
“The collar functions by releasing Bioiberica’s biologically derived skin health ingredients directly onto the pet’s skin, which are then spread across the body through the lipids of the skin,” the company’s press release states.
The product is sold under the name Atopivet Collar. The company calls the product a “world first” because it gives pet owners an alternative to the traditional topical and oral treatments usually prescribed to treat pet atopic dermatitis. Instead, the company says, the collar is a more convenient application.
“Thanks to its dual maintenance and sparing effect, the Atopivet Collar is well equipped to aid in the cyclical nature of atopic dermatitis and help reduce flare-ups,” said Sergi Segarra, Bioiberica’s R&D project manager, animal health, in a press release. He said the collar can take a month or two to have an effect.
The collar is lavender-scented and waterproof. “We recognized the need for an accessible, effective option that gives owners the freedom to choose a noninvasive, practical alternative to traditional oils, creams, and tablets,” added Jordi Flores Garcia, the company’s marketing director, companion-animal division. “While the collar format is a completely new and innovative approach to supporting pets’ skin health, the ingredients within it have already been shown to be an effective aid for skin conditions like atopic dermatitis, giving vets and pet owners alike assurance of its results.”
So far, Atopivet Collar has launched in the U.S. and Spain. It will launch in Europe soon, the firm says.